CliffBio
small molecule

SODIUM IODIDE I 123

SODIUM IODIDE I-123

Loss of exclusivity—loss of exclusivity
CompanyCurium Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameSODIUM IODIDE I 123
Active ingredientSODIUM IODIDE I-123
Strength200uCi
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 1989
Marketing statusRX

More from Curium Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.